Abstract:Apigenin, a flavonoid isolated from plants, provides protection against non-alcoholic fatty liver disease. However, the mechanism by which apigenin decreases lipid accumulation in the liver is unclear. In this study, we investigated the molecular mechanism underlying the beneficial effect of apigenin on the hepatic deregulation of lipid metabolism. Oleic acid (OA)-induced lipid accumulation in human hepatoma cells (Huh7 cells) was used as an in vitro model. Western blot analysis was used for evaluating protein expression. Oil red O staining, Nile red staining, and conventional assay kits were used to assess the level of lipids. Immunocytochemistry was performed to observe mitochondrial morphology. Seahorse XF analyzer was used to measure mitochondrial bioenergetics. Treatment with OA induced lipid accumulation in Huh7 cells, which was attenuated by apigenin. Mechanistically, treatment with apigenin increased the expression of autophagy-related proteins including Beclin1, autophagy related gene 5 (ATG5), ATG7, and LC3II, and the formation of autophagolysosomes, leading to an increase in intracellular levels of fatty acids. Inhibition of autophagy by bafilomycin A1 or chloroquine abolished the protection of apigenin in OA-induced lipid accumulation. Apigenin up-regulated the protein expression related to the β-oxidation pathway including acyl-CoA synthetase long chain family member 1, carnitine palmitoyltransferase 1α, acyl-CoA oxidase 1, peroxisome proliferator activated receptor (PPAR) α, and PPARγ coactivator 1-α. Moreover, apigenin increased the mitochondrial network structure and mitochondrial function by increasing the protein expression related to the process of mitochondria fusion and mitochondrial function. Collectively, our findings suggest that apigenin ameliorates hepatic lipid accumulation by activating the autophagy-mitochondrial pathway.

Apelin-13 Inhibits Lipid Accumulation in Human Hepatocytes

Apelin Protects Against Liver X Receptor-Mediated Steatosis Through AMPK and PPARα in Human and Mouse Hepatocytes.

Correction: Apelin Ameliorates TNF-α-Induced Reduction of Glycogen Synthesis in the Hepatocytes Through G Protein-Coupled Receptor APJ

Apelin decreases lipolysis via G(q), G(i), and AMPK-Dependent Mechanisms

Protective Effect of APLN Against Liver X Receptor‐mediated Hepatic Steatosis Through HG11/APLNR in Human and Mouse Hepatocytes

Apelin Inhibits Adipogenesis and Lipolysis Through Distinct Molecular Pathways

Apelin-13 Increases Expression of ATP-binding Cassette Transporter A1 Via Activating Protein Kinase C Α Signaling in THP-1 Macrophage-Derived Foam Cells.

Apigenin Reduces the Excessive Accumulation of Lipids Induced by Palmitic Acid Via the AMPK Signaling Pathway in HepG2 Cells

Apelin-13 Impedes Foam Cell Formation by Activating Class Iii Pi3k/Beclin-1-Mediated Autophagic Pathway

Apelin-13 Induces Autophagy in Hepatoma Hepg2 Cells Through Erk1/2 Signaling Pathway-Dependent Upregulation of Beclin1

Apelin Suppresses Apoptosis of Human Osteoblasts

Apelin-13 inhibits lipopolysaccharide-induced endothelial cells apoptosis by regulating reactive oxygen species production

Fc-apelin Fusion Protein Attenuates Lipopolysaccharide-Induced Liver Injury in Mice

Apelin–APJ Induces ICAM-1, VCAM-1 and MCP-1 Expression Via NF-κB/JNK Signal Pathway in Human Umbilical Vein Endothelial Cells

Apelin/APJ Signaling is a Critical Regulator of Statin Effects in Vascular Endothelial Cells--brief Report.

Apelin‐13's Actions in Controlling Hypertension‐Related Cardiac Hypertrophy and the Expressions of Inflammatory Cytokines

Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction

Apigenin Reduces Lipid Droplet Accumulation in Hepatocytes by Enhancing Chaperone-Mediated Autophagy Via AMPK

Regulation of Apelin-13 on Bcl-2 and Caspase-3 and Its Effects on Adipocyte Apoptosis

Apigenin ameliorates hepatic lipid accumulation by activating the autophagy-mitochondria pathway

The apelin-13 peptide protects the heart against apoptosis through the ERK/MAPK and PI3K/AKT signaling pathways.